The association between primary Sjogren’s syndrome and non-Hodgkin’s lymphoma: a systematic review and meta-analysis of cohort studies

• Published in: Clinical rheumatology Vol. 43; no. 7; pp. 2177 - 2186
• Main Authors: Ansari, Narges, Salesi, Mansour
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2024; Springer Nature B.V
• Subjects: Acuity; adulthood; Autoimmune diseases; Cohort analysis; Cohort Studies; computer software; Data collection; demographic statistics; Female; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin - epidemiology; Male; Medicine; Medicine & Public Health; Meta-analysis; Non-Hodgkin's lymphoma; Review Article; Rheumatology; risk; Risk Factors; Sjogren's syndrome; Sjogren's Syndrome - complications; Sjogren's Syndrome - epidemiology; Systematic review; Lymphoma, Non-Hodgkin; Sjogren’s syndrome; Diffuse small cleaved cell lymphoma; Sicca syndrome
• ISSN: 0770-3198; 1434-9949; 1434-9949
• DOI: 10.1007/s10067-024-06993-6

Primary Sjögren’s syndrome (pSS), a chronic autoimmune condition, has been associated with an increased risk of several cancers. This study aims to delve into the relationship between pSS and the potential development of non-Hodgkin’s lymphoma (NHL) utilizing an in-depth systematic review and meta-analysis approach. To thoroughly explore the topic, we conducted a thorough examination of the literature, drawing from reputable databases such as ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar. Our data collection spanned until February 8, 2024, with no time limitation. Data were analyzed with Stata 14 software at a significance threshold of p  < 0.05. We examined 15 cohort studies encompassing a total of 50,308 individuals from 1997 to 2023. The findings revealed a substantial link between pSS and the risk of NHL, evident across all demographics. Specifically, the standardized incidence ratio (SIR) was generally 8.78 (95% CI 5.51, 13.99), with similar trends observed in both men (SIR, 6.29; 95% CI 1.93, 20.51) and women (SIR, 9.60; 95% CI 5.89, 15.63). Additionally, the SIR (10.50 (95% CI 7, 15.75)), HR (2.82 (95% CI 1.28, 6.18)), and OR (10.50 (95% CI 3.04, 36.28)) indices further supported this association. Furthermore, the risk of non-NHL associated with pSS was noticeable across different age groups of 40–49 years (SIR, 30.13; 95% CI 14.62, 62.08), 50–59 years (SIR, 9.12; 95% CI 5.13, 16.19), and 60–69 years (SIR, 9; 95% CI 4.68, 17.32). pSS substantively augments the likelihood of NHL manifestation. It notably impacts females and those in earlier stages of adulthood with more acuity than males and older cohorts.